Bone metastasis pattern in initial metastatic breast cancer: a population-based study

Abstract

PurposeBone is one of the most common sites of breast cancer metastasis, and population-based studies of patients with bone metastasis in initial metastatic breast cancer (MBC) are lacking.Materials and methodsFrom 2010 to 2013, 245,707 breast cancer patients and 8901 patients diagnosed with initial bone metastasis were identified by Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Multivariate logistic and Cox regression were used to identify predictive factors for the presence of bone metastasis and prognosis factors. Kaplan–Meier method and log-rank test were used for survival analysis.ResultsEight thousand nine hundred one patients with initial MBC had bone involvement, accounting for 3.6% of the entire cohort and 62.5% of the patients with initial MBC. Also, 70.5% of patients with bone metastasis were hormone receptor (HR) positive (HR+/human epidermal growth factor receptor 2 [HER2]−: 57.6%; HR+/HER2+: 12.9%). Patients with initial bone metastasis had a better 5-year survival rate compared to those with initial brain, liver, or lung metastasis. HR+/HER2− and HR+/HER2+ breast cancer had a propensity of bone metastasis in the entire cohort and were correlated with better prognosis in patients with initial bone metastasis. Local surgery had significantly improved overall survival in initial MBC patients with bone metastasis.ConclusionOur study has provided population-based estimates of epidemiologic characteristics and prognosis in patients with bone metastasis at the time of breast cancer diagnosis. These findings would lend support to optimal surveillance and treatment of bone metastasis in breast cancer.

Real-World Study of the Incidence, Risk Factors, and Prognostic Factors Associated with Bone Metastases in Women with Uterine Cervical Cancer Using Surveillance, Epidemiology, and End Results (SEER) Data Analysis

“…Patients with cancer of the uterine cervix have been reported to have a relatively lower incidence of bone metastases when compared with cancer of the breast, lung, and prostate [ 17 – 19 ]. The present study showed that 2.42% of the study cohort of women with cervical cancer had bone metastases when initially diagnosed, which was a similar finding to that of the study conducted by Thanapprapasr et al (1.1%) [ 6 ], but was lower than that found in other studies [ 8 , 20 , 21 ].…”

“…The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) was established in 1973, which includes approximately 30% of the total US population and provides an important data source for epidemiologic analysis [ 17 ]. Therefore, the aims of this study were to analyze the SEER database to determine the incidence and the risk factors for bone metastases in women with bone metastases on initial diagnosis of uterine cervical cancer, and to determine the overall survival, prognosis, and risk factors for patients who present with cervical cancer associated with bone metastases.…”

Could local surgery improve survival in de novo stage IV breast cancer?

“…The skeleton is the most common site of metastasis in breast cancer patients [ 36 ]. Patients with skeletal metastasis are more sensitive to systemic therapy and have relatively better outcomes than patients with metastasis to other sites [ 37 ].…”

Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Suppresses Migration of Bone‐Metastatic Breast Cancer Cells via OPN‐FAK/ERK/NF‐κB Axis

“…Metastasis is a severe threat to the survival of breast cancer patients worldwide [1,2], and bone metastasis occurs in approximately 65% of advanced breast cancer patients. Patients with bone metastasis suffer from bone pain, pathological fractures, hypercalcemia, and spinal cord compression, and the five-year survival rate is about 20% [3,4]. Conventional therapeutic approaches against bone metastasis include radiotherapy, chemotherapy, targeted therapy, endocrine therapy, and bone-modulating drug therapy.…”